194 related articles for article (PubMed ID: 18655952)
1. Controversial issues in thromboprophylaxis with low-molecular weight heparins in palliative care.
Tassinari D; Santelmo C; Scarpi E; Tombesi P; Sartori S
J Pain Symptom Manage; 2008 Aug; 36(2):e3-4. PubMed ID: 18655952
[No Abstract] [Full Text] [Related]
2. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
3. Prevention of venous thromboembolism after acute spinal cord injury with low-dose heparin or low-molecular-weight heparin.
Paciaroni M; Ageno W; Agnelli G
Thromb Haemost; 2008 May; 99(5):978-80. PubMed ID: 18449438
[No Abstract] [Full Text] [Related]
4. Low-molecular-weight heparin for thromboprophylaxis.
Camporese G; Bernardi E
Curr Opin Pulm Med; 2009 Sep; 15(5):443-54. PubMed ID: 19593139
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism.
Lindqvist PG; Bremme K; Hellgren M;
Acta Obstet Gynecol Scand; 2011 Jun; 90(6):648-53. PubMed ID: 21314819
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulants for thrombosis prophylaxis following surgery: a continuing saga.
Caprini JA
Thromb Haemost; 2008 Jun; 99(6):993-4. PubMed ID: 18521498
[No Abstract] [Full Text] [Related]
7. Finding the evidence for thromboprophylaxis in palliative care: first let us agree on the question.
Noble S; Johnson M
Palliat Med; 2010 Jun; 24(4):359-61. PubMed ID: 20507865
[No Abstract] [Full Text] [Related]
8. Risks and benefits of low molecular-weight heparin and target-specific oral anticoagulant use for thromboprophylaxis in medically ill patients.
Hale G; Brenner M
Am J Cardiovasc Drugs; 2015 Oct; 15(5):311-22. PubMed ID: 25957095
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
10. AANA Journal course: update for nurse anesthetists--low molecular weight heparin: pharmacology and regional anesthetic implications.
Thames BC; Allen DO
AANA J; 2000 Aug; 68(4):357-64. PubMed ID: 11125607
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism in at-risk pregnant women: a review.
Duhl AJ
J Reprod Med; 2008 Sep; 53(9):657-66. PubMed ID: 18839817
[TBL] [Abstract][Full Text] [Related]
12. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
[TBL] [Abstract][Full Text] [Related]
13. Early administration of low molecular weight heparin after spontaneous intracerebral hemorrhage. A safety analysis.
Kiphuth IC; Staykov D; Köhrmann M; Struffert T; Richter G; Bardutzky J; Kollmar R; Mäurer M; Schellinger PD; Hilz MJ; Doerfler A; Schwab S; Huttner HB
Cerebrovasc Dis; 2009; 27(2):146-50. PubMed ID: 19039218
[TBL] [Abstract][Full Text] [Related]
14. The safety and usefulness of low molecular weight heparins and unfractionated heparins in patients with acute stroke.
Kiphuth IC; Köhrmann M; Huttner HB; Schellinger PD
Expert Opin Drug Saf; 2009 Sep; 8(5):585-97. PubMed ID: 19614560
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban for thromboprophylaxis.
Lippi G; Franchini M; Targher G
N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009674
[No Abstract] [Full Text] [Related]
16. Perioperative anticoagulant management.
Grant PJ; Brotman DJ; Jaffer AK
Med Clin North Am; 2009 Sep; 93(5):1105-21. PubMed ID: 19665623
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
[TBL] [Abstract][Full Text] [Related]
18. [Marcumarized patient must have surgery. Playing it safe with low molecular weight heparin bridging].
MMW Fortschr Med; 2005 Jun; 147(22):51. PubMed ID: 15977637
[No Abstract] [Full Text] [Related]
19. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study.
Noble SI; Nelson A; Turner C; Finlay IG
BMJ; 2006 Mar; 332(7541):577-80. PubMed ID: 16459340
[TBL] [Abstract][Full Text] [Related]
20. Prevention of venous thromboembolism in hospitalized medical patients.
Lenchus JD; Jaffer AK
Mt Sinai J Med; 2008 Oct; 75(5):449-53. PubMed ID: 18828167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
